Applied Micro's (AMCC) management appears to believe that it can pull the wool over investors' eyes regarding its fabled X-Gene strategy indefinitely. Unfortunately, as I listened to the Q&A, none of my criticisms of the Applied Micro executive team were quelled. In fact the vague, PR-like responses to questions regarding its upcoming "X-Gene" product lend further credibility to my case that at the end of the day, X-Gene will be a textbook example of "over promise, under deliver."
Brushing Off The Intel Threat
Consider the following question posed by Patrick Wang of Evercore Partners from the latest conference call,
When we take a look at X Gene over the course of this year you'll have a...